Search
Showing results for "Childhood interstitial lung disease "
Maternal occupational pesticide exposure during pregnancy and/or paternal occupational pesticide exposure around conception have been suggested to increase...
Early intervention is being touted as the key to preventing lung damage in children with cystic fibrosis.
Persistent respiratory bacterial infections are a clinical burden in several chronic inflammatory airway diseases and are often associated with neutrophil infiltration into the lungs. Following recruitment, dysregulated neutrophil effector functions such as increased granule release and formation of neutrophil extracellular traps (NETs) result in damage to airway tissue, contributing to the progression of lung disease.
Childhood asthma begins as wheeze (a whistling sound produced by the airways during breathing) during preschool age.
This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches
This Research Note has explored the strengths, risks and potential complexity of adaptive trials
The Wal-yan Respiratory Research Centre is proud to have a team of researchers taking part in, and contributing to, the outstanding scientific programme of the European Respiratory Society International Congress, taking place in Milan.
Current continuous glucose monitoring (CGM) systems measure glucose levels in the interstitial fluid to estimate blood glucose concentration.
Respiratory syncytial virus (RSV) is a major cause of respiratory infection with a higher burden in Aboriginal and Torres Strait Islander infants and children. We conducted a pilot qualitative study identifying disease knowledge and willingness to immunise following the changing immunisation landscape for infant RSV in 2024.
The 2023 Australian guideline for assessing and managing cardiovascular disease risk provides updated evidence-based recommendations for the clinical assessment and management of cardiovascular disease (CVD) risk for primary prevention. It includes the new Australian CVD risk calculator based on an equation developed from a large New Zealand cohort study, customised and recalibrated for the Australian population. The new guideline replaces the 2012 guideline that recommended CVD risk assessment using the Framingham risk equation.